-
公开(公告)号：US20220062419A1
公开(公告)日：2022-03-03
申请号：US17227753
申请日：2021-04-12
Applicant: IMMUNOLIGHT, LLC , DUKE UNIVERSITY
Inventor： Mark OLDHAM , Justus ADAMSON , Mark W. DEWHIRST , Paul YOON , Harold WALDER , Frederic A. Bourke, JR. , Zakaryae FATHI , Wayne F. BEYER, JR.
IPC: A61K41/00 , A61N5/06 , A61K31/655 , A61K33/02 , A61K31/409 , A61K31/525 , A61K31/352 , A61K31/403 , A61K33/242 , A61K33/244 , A61K33/24 , A61N5/10
Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
-
Patent Agency Ranking
公开(公告)号：US20180344850A1
公开(公告)日：2018-12-06
申请号：US15992852
申请日：2018-05-30
Applicant: IMMUNOLIGHT, LLC , DUKE UNIVERSITY
Inventor： Frederic A. BOURKE, JR. , Mark DEWHIRST , Neil SPECTOR , Paul YOON , Justus ADAMSON , David ALCORTA , Kim LYERLY , Leihua LIU , Takuya OSADA , Mark OLDHAM , Zakaryae FATHI , Wayne F. BEYER , Harold WALDER
Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.
-
公开(公告)号：US20200009398A1
公开(公告)日：2020-01-09
申请号：US16554831
申请日：2019-08-29
Applicant: IMMUNOLIGHT, LLC. , DUKE UNIVERSITY
Inventor： Mark OLDHAM , Zakaryae FATHI , Wayne F. BEYER , Frederic A. BOURKE, JR. , Harold WALDER , Mark DEWHIRST , Neil L. SPECTOR , Paul YOON , Justus ADAMSON , David ALCORTA , Kim LYERLY , Leihua LIU , Takuya OSADA
IPC: A61N5/06 , A61K31/352 , A61K41/00
Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
-
公开(公告)号：US20190184190A1
公开(公告)日：2019-06-20
申请号：US16322178
申请日：2017-08-01
Applicant: IMMUNOLIGHT, LLC , DUKE UNIVERSITY
Inventor： Harold WALDER , Frederic A. BOURKE , Zakaryae FATHI , Wayne BEYER , Mark OLDHAM , Justus ADAMSON , Paul YOON
CPC classification number: A61N5/062 , A61K33/42 , A61K41/00 , A61K41/0057 , A61N5/10 , A61N2005/1098 , A61P35/00
Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.
-
公开(公告)号：US20180311355A1
公开(公告)日：2018-11-01
申请号：US15770926
申请日：2016-10-26
Applicant: IMMUNOLIGHT, LLC. , DUKE UNIVERSITY
Inventor： Mark OLDHAM , Justus ADAMSON , Mark W. DEWHIRST , Paul YOON , Harold WALDER , Frederic A. BOURKE , Zakaryae FATHI , Wayne F. BEYER
CPC classification number: A61K31/655 , A61K31/352 , A61K31/403 , A61K31/409 , A61K31/525 , A61K33/02 , A61K41/0066 , A61N5/062 , A61N5/0624 , A61N2005/065 , A61N2005/1095 , A61N2005/1098 , Y02A50/393
Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
-
公开(公告)号：US20170157418A1
公开(公告)日：2017-06-08
申请号：US15434871
申请日：2017-02-16
Applicant: IMMUNOLIGHT, LLC , DUKE UNIVERSITY
Inventor： Mark OLDHAM , Zakaryae FATHI , Wayne F. BEYER , Harold WALDER , Frederic A. BOURKE, JR. , Mark DEWHIRST , Neil L. SPECTOR , Paul YOON , Justus ADAMSON , David ALCORTA , Kim LYERLY , Leihua LIU , Takuya OSADA
IPC: A61N5/06 , A61K31/352 , A61K41/00 , A61N5/10
CPC classification number: A61N5/062 , A61K31/352 , A61K31/525 , A61K33/00 , A61K35/00 , A61K38/00 , A61K41/0066 , A61N5/10 , A61N2005/0661 , A61N2005/0662 , A61N2005/1089 , A61N2005/1098
Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
-
-
-
-
-
Search Results
6
records
(took 0.04 seconds)
